English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Interferon-ribavirin combination therapy is the mainstay treatment for chronic hepatitis C today. In view of its very common use, we investigated the adverse drug reactions through a retrospective review of medical records of chronic hepatitis C patients who underwent such therapy. We also determined their current condition by investigating hemoglobin levels, white blood cell counts and platelet counts.Subjects were 20 chronic hepatitis C patients (7 females and 13 males, mean age 53.6 years) who were hospitalized in the Department of Gastroenterology of Kasugai Municipal Hospital to undergo interferon-ribavirin combination therapy. Ten patients were classified as HCV serotype 1, and 10 as HCV serotype 2. Four patients discontinued the therapy. Bloodtests showed that the rate at which hemoglobin levels, white blood cell counts and platelet counts decreased tended to belower than before treatment.No notable adverse drug reactions were observed in this study, those that did occur were similar to those seen with interferon monotherapy and with the exception of muscle pain, there were no significant differences. However, many individualdifferences were seen in terms of severity, time of onset and duration of symptoms. This confirmed the need for guidanceto be geared towards individual patients. Based on the results of our investigation, we revised our brochure on interferonribavirin combination therapy to give a fuller explanation of the adverse reactions. We feel that it is very important for patients to have a good understanding of the possible adverse reactions beforehand and to make an adequate response whenthey occur during therapy.

iryō yakugaku/iryou yakugaku

Retrospective Study on Adverse Reactions Occurring during Interferon-ribavirin Combination Therapy and Revision of Pamphlet on the Therapy to Give a Fuller Explanation of Adverse Reactions